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Summary Selective venous sampling catheterisation was performed in 19 patients with medullary thyroid
carcinoma without known distant metastases for persistent hypercalcitoninaemia after surgery. Calcitonin (CT)
gradients were found in the neck and/or the mediastinum in 18 patients and in five patients at distant sites
also. After venous catheterisation, 13 patients were subjected to repeat surgery. Neck and/or mediastinal
tumour foci were found in 12 patients at the sites of the CT gradients. Of these, nine patients had only
cervicomediastinal CT gradients: after reoperation, the serum CT level normalised in one, significantly
decreased in five, and did not change in three, and no neck relapse occurred after a mean follow-up of 5.3
years. Distant metastases emerged clinically in all five patients with distant gradients and in only one of the 14
patients with no distant gradient. In conclusion, selective venous catheterisation is the most sensitive tool for
the localisation of residual disease and for the early detection of distant metastases. However, in patients with
only local disease, biochemical cure is rarely obtained after reoperation.
Medullary thyroid carcinoma (MTC) spreads early to
regional lymph nodes in the neck and mediastinum and to
distant sites in the liver, lungs and bones (Grauer et al.,
1990).
The aim of initial surgery is to remove all neoplastic foci.
It consists of a total thyroidectomy with bilateral lymph node
dissection in the neck and the upper mediastinum (Wahl &
Roher, 1988). The normalisation of the serum calcitonin
(CT) level after surgery is a strong indicator that neoplastic
tissue has been totally removed. However, this is achieved in
only 20% of patients with clinical disease (Parmentier et al.,
1985). In others, persistently elevated CT levels indicate the
presence of residual disease. If localised, this may warrant
further surgery. However, a complete work-up, including
ultrasonography, computerised tomography or magnetic
resonance imaging and bone scintigraphy, frequently yields
no positive evidence of localised tumours in these patients
with elevated CT levels. Furthermore, owing to previous
surgical procedures, the significance of any abnormality may
be ambiguous. Scintigraphic procedures have not proved to
be sensitive enough to be useful as a routine.
Selective venous sampling catheterisation appeared to be a
sensitive and specific tool for localising the origin of serum
CT in patients with elevated CT levels and no other evidence
of disease (Ben Mrad et al., 1989; Gautvik et al., 1989;
Frank-Raue et al., 1992). However, given the slow growth
rate of most MTCs, the follow-up was too short in these
series to elucidate the significance of extracervical gradients
and to conclude that this technique could be useful, in terms
of relapse and survival rates.
The present study is based on 19 patients, with a mean
follow-up of 5.5 years after selective venous catheterisation.
Eight of these patients have previously been reported (Ben
Mrad et al., 1989).
Before selective venous catheterisation, all patients were
subjected to a clinical examination, including chest radio-
graphy, ultrasonography of the neck and liver, computerised
tomography of the neck, chest and abdomen and bone scin-
tigraphy. This work-up only permitted the discovery of
involved cervical or mediastinal lymph nodes in six patients
(nos. 1, 4, 6, 13, 18 and 19).
The selective venous sampling catheterisation procedure
has already been reported (Ben Mrad et al., 1989). It was
performed by the femoral route using a Cook SF 2-cm-long
catheter with a 1200 angle and one side-hole tip (Cook,
SARL, Paris, France). A standard procedure was used: a
mean of 25 samples was obtained for each patients from iliac
veins, inferior vena cava, hepatic and renal veins, the right
auricle, superior vena cava, mediastinal, brachiocephalic,
internal jugular veins and the remaining thyroid veins.
Peripheral venous blood samples were obtained by needle
puncture of a forearm vein.
Serum CT was measured using a polyclonal antibody
radioimmunoassay (Calmettes et al., 1979) (normal range less
than 0.25 ngml-') and, since 1986, using a monoclonal
antibody immunoradiometric assay (Motte et al., 1988) (nor-
mal range less than lOpgmh1-). Intra-assay variability was
less than 7% and inter-assay variability less than 15%. The
CT gradient was expressed as the ratio of CT levels in the
selective sample and in the basal peripheral sample. All
gradients equal to or above 1.2 were considered as
significant.
After selective venous catheterisation, 13 patients under-
went further surgery, of whom six were also subjected to
post-operative external radiotherapy to the neck and upper
mediastinum. The other six patients did not undergo further
surgery. External radiotherapy to the neck and mediastinum
was performed in two patients (nos. 17 and 19), and
chemotherapy in patient 16.
Patients and methods
From 1973 to 1992, 19 patients with MTC underwent selec-
tive venous sampling catheterisation for high serum CT levels
after surgery (Table I). This was performed in nine patients
after primary surgery and in ten after iterative surgical proce-
dures. Three patients (nos. 5, 10 and 15) had received exter-
nal radiotherapy to the neck and mediastinum.
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Results
Selective venous sampling catheterisation
Peripheral blood CT level was not predictive of the extension
of MTC given that it was either high (patients 3, 4 and 16) or
relatively low (patients 5 and 18) in some patients with
gradients at distant sites.
In patient 15, whose surgical procedure was complete, no
CT gradient was found. In the other 18 patients, significant
gradients, ranging from 1.2 to 8.3, were found in the neck
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Table I Characteristics ofthe 19 patients and treatment procedures before selective
venous catheterisation
Patient Age
no. (years) Sex MTC
1 50 M S
2 44 M S
12 F MEN lIb
35 M MEN Ila
42 F S
35 F MEN Ila
42 M S
30 M S
41 M S
Thyroid
Tr
TIT
Surgery
Lymph nodes
RCLND (N+)
RCLND (N+)
Partial LCLND (N+)
TT B
Subtotal RL
lobectomy
TT P;
TT B
L lobectomy L
R lobectomy PE
Subtotal L
lobectomy
ICLND (N+)
lartial CLND (N+)
ICLND (N+)
,CLND (N-)
laratracheal
groove (N+)
10 47 M S TT BCLND (N+)
11 52 M S L lobectomy LCLND (N+)
12 14 M MEN IIb TT BCLND (N+)
13 28 F S TT BCLND (N-)
14 39 M S TT RCLND (N+)
15 6 F MEN IIb TT BCLND (N+)
16 24 F MEN Ilb TT BCLND (N+)
17 18 F MEN hIa TT BCLND (N+)
18 34 F MEN Ila TT BCLND (N+)
19 31 M S TT BCLND (N+)
S, sporadic; MEN, multiple endocrineneoplasia; TT, total thyroidectomy; R, right;
L, left; B, bilateral; CLND, cervical lymph node dissection.
Table II Basal serum CT gradient values in and outside the neck in the hypercalcitoninaemic patients subsequently subjected to neck surgery after
selective venous catheterisation (SVS), serum peripheral CT evolution and outcome
Outcome
CT level Distant
Peripheral after metastases Total duration
Patient CT level CTgradients Cervical surgery Time after after SVS
no. (ml-') Site Value surgery (ml-') Site SVS (years) (years)
1 1.2 ng R cervical 8.3 R cervical: ION+/31 0.50 ng None 7.7 Alive
Mediastinum: 6N+/6
2 128 pg L cervical 3.5 B cervical IN+/3 129 pg None 2.7 Alive
R cervical 4.8
3 5.5 ng R brachiocephalic 1.8 B cervical 31N+/78 2.24 ng 5 Dead
R auricle 1.7 Lungs liver 2
4 1580 pg R cervical 2.5 R cervical 6610 pg 7.7 Dead
R mediastinum+
Superior vena cava 1.4 Lungs 5
Suprahepatic 1.6 Liver
L iliac 1.4 Lumboaortic
iliac nodes
5 2.2 ng Inferior thyroid 3.5 R cervical 3N+ 1.1 ng 10.6 Alive
Suprahepatic 2.7 Liver 5
L iliac 4.1
6 249 pg R cervical 2.2 R cervical 2N+/3 122 pg 2.5 Alive
L cervical 1.3 None
Superior vena cava 1.8
7 2020 pg Superior vena cava 1.7 R paratracheal 681 pg 1.1 Alive
grove 6N+ None
8 0.47 ng Inferior thyroid 4.1 L lobectomy = MTC < 10 pg 5.0 Alive
None
R subclavian 2.5 R cervical 48N-/48
9 2450 pg Inferior thyroid 4.0 Bilateral paratracheal 1160 pg None 10.7 Alive
4N+/12
10 7.2 ng L brachiocephalic 2.3
Superior vena cava 2.2 Mediastinum N+ 3.15 ng None 12.3 Alive
11 120pg L cervical 1.5 Lcervical 4N+/10 134pg None 3.2 Alive
12 386 pg R cervical 1.3 Benign thyroid 335 pg None 3.3 Alive
remnants
13 1190 pg L cervical 2.2 L cervical 950 pg None 2.4 Alive
Superior vena cava 2.1
L brachiocephalic 2.3
3
4
5
6
7
8
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TableIII Basal serum CTgradientvaluesinandoutsidetheneckin thehypercalcitoninaemic patients notreoperated afterselective venous
catheterisation, serum peripheral CT evolution and outcome
Outcome
Distant
Peripheral CT level metastases Total duration
Patient CT level CTgradients Cervical (ml-') Time after after SVS
no. (ml-') Site Value surgery last control Site SVS (years) (years)
14 390 pg L subclavian 1.6 1,160 pg Lungs-bones 2 2.5 Alive
R brachiocephalic 1.2 Liver
15 2,000 pg - 2,000 pg None 1.6 Alive
16 228 pg R cervical 2.3 3,890 pg 2.5 Alive
R auricle 2.4 (chemotherapy) Lung 1.5
Suprahepatic 2.3 Liver 1.5
R iliac 2.2 Spine 1.5
(D12-L5)
17 74ng R subclavian 1.5 ll9ng None 1.7 Alive
L brachiocephalic 1.4 (ETR neck-
mediastinum)
18 0.30 ng L cervical 2.5 1,720 pg 9.7 Alive
R cervical 1.8
Suprahepatic 1.7 Liver 1.0
19 133 ng Superior vena cava 1.5 52,400 pg Mediastinal 1.0 12.9 Dead
(ETR neck- recurrence
mediastinum)
thermotherapy
ETR, external radiotherapy.
and/or the upper mediastinum. In addition, gradients were
found at distant sites in five patients. Selective venous
catheterisation gave evidence of a gradient at the site of the
abnormality in all six patients in whom the previous work-up
had shown abnormalities, and in two of them (nos. 4 and 18)
also at sites where no abnormality had been found.
Surgery after venous catheterisation (Table II)
Thirteen patients with CT gradients ranging from 1.3 to 8.3
in the neck and/or mediastinum underwent further surgery.
In one patient (no. 12) with a CT gradient equal to 1.3, no
tumour tissue was found; 3.3 years after venous catheterisa-
tion, the serum CT level is stable and there is no other
evidence of disease.
In the other 12 patients, tumour foci were found at all the
sites of the gradients. Among the nine patients with no
distant gradient, the CT level normalised only in patient 8
after excision of a residual thyroid lobe, which contained a
MTC focus, whereas all the dissected lymph nodes were free
of disease. The CT level decreased in five patients and did
not change post-operatively in the other three patients. Six of
these patients subsequently received irradiation to the neck
and upper mediastinum, but no further decrease in serum
CT was observed. In these nine patients, with a mean follow-
up of 5.3 years (1.1- 12.3 years) after venous catheterisation,
no neck relapse or distant metastasis occurred. Among the
three patients who also had distant gradients, the CT level
did not decrease after surgery. No relapse occurred in the
neck, but all three patients developed distant metastases at
the sites of the gradients 2-5 years after venous catheterisa-
tion.
Sixpatients were not reoperated after venous catheterisation
(Table III)
Patient 15 with no CT gradient has stable disease 1.6 years
after venous catheterisation. The other five patients had
gradients in the neck and/or in the mediastinum, ranging
from 1.2 to 2.5. Two patients (nos. 16 and 18) were not
operated on again for distant gradients and distant meta-
stases emerged clinically at the sites of the gradients 1-1.5
years after venous catheterisation.
The other three patients (nos. 14, 17 and 19) had no
distant gradient. They refused further surgery. Patient 14
Table IV Detection oftumour foci in the neck and at distant sites by
selective venous catheterisation
Subsequent emergence of
Neckfoci (surgery) distant metastases
Yes No Yes No
CT gradient
Yes 12 1 5 0
No 0 0 1 13
developed bone, lung and liver metastases 2 years after
venous catheterisation. Patients 17 and 19 were irradiated. In
patient 17 a slight increase in the CT level was observed 1.7
years after venous catheterisation. Patient 19, with a CT
gradient in the superior vena cava, developed a slowly grow-
ing mediastinal recurrence, which led to death 12.9 years
after venous catheterisation.
Discussion
The present data confirm that, in patients with a high serum
CT level after surgery, selective venous catheterisation is the
most sensitive and the most specific method for the localisa-
tion of MTC tissue (Table IV) (Ben Mrad et al., 1989;
Gautvik et al., 1989; Frank-Raue et al., 1992). It was pos-
sible to localise small foci of MTC even in patients with no
other evidence of disease. Venous catheterisation detected all
neoplastic foci found at further neck surgery. Venous
catheterisation showed CT gradients in the neck or media-
stinum, and in some patients at distant sites, even in those
with relatively low basal CT levels. Therefore there is no
cut-off value for the CT level below or above which neoplas-
tic foci in the neck or at distant sites may be assumed to
exist. This is in agreement with the findings of a previous
study (Gautvik et al., 1989).
CT gradients were frequently found in the mediastinum.
Venous catheterisation is particularly interesting in this loca-
tion, which is frequently involved (Wahl & Roher, 1988),
since small lymph node metastases may be difficult to demon-
strate by other means, especially in patients who have
already undergone surgery.1144 N. ABDELMOUMENE et al.
Gradients detected by venous catheterisation corresponded
to an MTC tumour focus in the neck or in the mediastinum
in 12 of 13 surgical procedures, or to distant metastases as
shown by their clinical appearance during the follow-up in all
the five patients with distant gradients. After a mean follow-
up of 4.7 years, only one of the 14 patients without distant
gradient developed metastases in the lungs, bones and liver.
Therefore, venous catheterisation should be used in the
routine management of patients with persistent elevated CT
levels after initial surgery, before any other therapeutic pro-
cedure, and particularly for the diagnosis of liver metastases,
which are known to have a major prognostic impact. Their
presence could either be demonstrated at an early stage or
excluded if no CT gradient is found in the hepatic vein (Ben
Mrad et al., 1989; Gautvik et al., 1989). Among the five
patients with liver metastases detected by this procedure,
none had already been revealed by ulstrasonography or com-
puterised tomography. All were confirmed after a mean
follow-up of 3.1 years after venous catheterisation. Thus,
patients with distant gradients should not be subjected to
further locoregional procedures (surgery or external radio-
therapy), even if they have no other evidence of disease, since
distant metastases are likely to emerge in the following
months or years.
Of the three patients with cervical gradients only but who
refused further surgery, one developed a mediastinal recur-
rence despite radiotherapy and which led to death and the
other two had progressive disease.
In the nine patients without distant gradients, despite the
excision of tumour foci at the sites of the gradients, the CT
level normalised post-operatively in only one patient who
had no lymph node metastasis and decreased in the other five
patients. This low cure rate is in agreement with the findings
of some series (Van Heerden et al., 1990), but is lower than
in series using microsurgical reoperation (Tisell et al., 1986;
Frank-Raue et al., 1992) in which a biochemical cure in
21-36% of patients has been reported. However, none of
our patients developed a neck recurrence. Therefore, they
may be controlled for a long period of time by external
irradiation or, because of the slow growth rate of most
MTCs (Van Heerden et al., 1990), the clinical emergence of
the disease may occur years later.
In conclusion, selective venous sampling catheterisation is
the most sensitive method available for the localisation of
persisting MTC after initial surgery and can aid decisions
regarding further therapy. In fact, one of the main benefits of
this procedure is the detection of distant spread. In these
patients, reoperation is not indicated, but a strict follow-up is
warranted and can be guided by venous catheterisation.
The authors are grateful to Lorna St Ange for editing the manuscript
and Katia Garbolen for her secretarial assistance.
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